CDO | Jotup

Leaders across every industry cite democratizing data and AI as the number one challenge to achieving their generative AI goals, according to a new MIT Technology Review Insights research report

Retrieved on:

Tuesday, January 9, 2024

CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- A new report by MIT Technology Review Insights explores the breakthroughs in data intelligence that will enable CIOs to reach their data and generative AI priorities across seven industries, namely retail and consumer packaged goods, healthcare and life sciences, manufacturing, financial services, telecommunications, media and entertainment, and the public sector.

Key Points:

"Organizations investing in unified data and governance platforms to fuel their AI and empower their workforces are positioned to lap the competition in realizing AI-based results."
The findings are as follows:
Real-time analytics and secure sharing are priorities in every industry to unleash the power of data truly.
Sixty-four percent of CIOs say the ability to securely share live data and AI assets across platforms is "very important."
Still, in every case, value creation will depend on access to data and AI across roles within the organization.

Leaders across every industry cite democratizing data and AI as the number one challenge to achieving their generative AI goals, according to a new MIT Technology Review Insights research report

Retrieved on:

Tuesday, January 9, 2024

CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- A new report by MIT Technology Review Insights explores the breakthroughs in data intelligence that will enable CIOs to reach their data and generative AI priorities across seven industries, namely retail and consumer packaged goods, healthcare and life sciences, manufacturing, financial services, telecommunications, media and entertainment, and the public sector.

Key Points:

"Organizations investing in unified data and governance platforms to fuel their AI and empower their workforces are positioned to lap the competition in realizing AI-based results."
The findings are as follows:
Real-time analytics and secure sharing are priorities in every industry to unleash the power of data truly.
Sixty-four percent of CIOs say the ability to securely share live data and AI assets across platforms is "very important."
Still, in every case, value creation will depend on access to data and AI across roles within the organization.

BoeFly's Latest Confidence Index Reveals Concerns About Rising Interest Rates Among Franchisors

Retrieved on:

Monday, January 8, 2024

CFOS, Growth, Beauty, Index, Health, CDO, Education, Publishing

This most recent index was used to assess whether significant shifts in franchisor executive confidence occurred throughout 2023, building upon data from the two previous quarterly surveys.

Key Points:

This most recent index was used to assess whether significant shifts in franchisor executive confidence occurred throughout 2023, building upon data from the two previous quarterly surveys.
According to the latest findings, franchisors are growing increasingly concerned about the rising interest rates and its impact on their domestic growth goals.
A major contributing factor to this uncertainty is the apprehension surrounding rising interest rates, with 86.7 percent of respondents indicating that current rates are negatively impacting their growth plans.
For a full report on the Franchise Growth Confidence Index survey findings, visit https://boefly.com/blog/boefly-franchise-growth-confidence-index-3/ .

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Retrieved on:

Friday, January 5, 2024

CFO, Pharming, CDO, PMV, Facility, General counsel, Growth, Human resources, Corporate development, G&A, Senior, Management

(Senior Vice President, Head of Clinical Development and Medical Affairs)

Key Points:

(Senior Vice President, Head of Clinical Development and Medical Affairs)
PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced key appointments across its leadership team.
Dr. Jalota joined PMV in 2019 and was promoted to Chief Development Officer (CDO) in May 2023.
Dr. Fellous joined PMV in 2022 and was promoted to Senior Vice President, Clinical Development and Medical Affairs in May 2023.
I also want to congratulate Mike, Rob, and Tim in their new and expanded roles at PMV.

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

Retrieved on:

Thursday, January 4, 2024

Doctor of Pharmacy, Conference, Pasteur Institute, Boehringer Ingelheim, Abivax, CDO, Clinical trial, JPMorgan Chase, Pharma, Altana, Pharmaceutical industry

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

Key Points:

Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer
Paul Gineste brings 25 years of experience in clinical development and strategy with leading international pharmaceutical and biotech companies.
Recently, Paul served as Vice President, Clinical Operations at Abivax, where he led the development of drug candidates from discovery through global Phase 3 programs.
Paris, France, January 4, 2024 - Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Paul Gineste as Chief Development Officer (CDO), effective January 1, 2024.
Scott Filosi, CEO of Evexta Bio, said: "I am delighted to welcome Paul as the new Chief Development Officer of Evexta Bio.

Wavestone Releases 2024 Data and AI Leadership Executive Survey

Retrieved on:

Tuesday, January 2, 2024

Synthetic media, Ethics, Fortune 1000, CDO, AI, Generative, Investment, Data, Organization, Foreword

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Wavestone has published the results of its 12th annual Data and AI Leadership Executive Survey of Fortune 1000 and Global data leadership. This year, 95.3% of survey participants held a C-suite title or were their company's corporate head of data and AI responsibilities, with 89.8% holding the title of Chief Data Officer (CDO) or Chief Data and Analytics Officer (CDAO) within their organization. These executives held their positions during 2023 at over 100 Fortune 1000 and Global data leadership organizations.

Key Points:

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Wavestone has published the results of its 12th annual Data and AI Leadership Executive Survey of Fortune 1000 and Global data leadership.
Wavestone has published its 12th annual Data & AI Leadership Executive Survey of Fortune 1000 & Global data leaders.
The Data and AI Executive Leadership Survey has evolved over the past dozen years and is now widely recognized as the longest running survey of Fortune 1000 and global data, analytics, and AI leaders.
Major findings of the 2024 Data and AI Leadership Executive Survey are:
Leading companies continue investments in data and analytics with the expectation of delivering business value.

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas

Retrieved on:

Thursday, December 28, 2023

Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.

Key Points:

Given this market potential, vast amounts of time and capital that have been invested to find an effective treatment for GA.
Earlier this year the FDA approved the first medicine for the treatment of GA, SYFOVRE®1 (pegcetacoplan injection) from Apellis.
In August of this year, a second product was approved for GA, IZERVAY™2(avacincaptad pegol intravitreal solution) from Iveric Bio, an Astellas company, with a similar profile to SYFOVE.
In the event the total Working Capital costs would amount to the total remaining amount under the Atlas funding program, i.e.

Bluecore Launches Identity Network for Enterprise Retailers

Retrieved on:

Monday, December 11, 2023

Marketing, Transparency, Movement, Acquisition, CMO, CDO, Behavior, ID, Intelligence, Automation

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Bluecore, a retail shopper identification and customer movement technology, today announced the launch of their Transparent ID Network.

Key Points:

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Bluecore, a retail shopper identification and customer movement technology, today announced the launch of their Transparent ID Network.
Now with the Transparent ID Network, Bluecore customers can increase shopper identification of new to website shoppers with significant speed.
With greater identification rates, enterprise retailers can increase marketing reach and revenue generation.
The Transparent ID Network is Soc I and Soc II compliant to meet the security needs of enterprise retailers and Bluecore’s Transparent ID reporting provides deep incrementality reporting to demonstrate where incremental reach translates into incremental revenue.

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

Retrieved on:

Monday, December 11, 2023

ESMO, Neoplasm, Immune system, LILRB2, CD47, HLA, Alpha globulin, Doctor of Philosophy, Therapy, KIR3DL1, CDO, Cancer, Inflammation, Myelocyte, CSO, Patient, LILRB1

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.

Key Points:

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
“We already have encouraging in vitro data demonstrating potent anti-tumor efficacy and primary cell data demonstrating an enhanced safety profile compared to competing CD47 targeting molecules,” said Osiris Marroquin Belaunzaran, PhD, CSO and co-founder of ImmunOs Therapeutics.
“We believe that HLA molecules can serve as a versatile backbone to develop novel therapies capable of stimulating the immune system of cancer patients to eliminate tumor cells.
Moreover, we are also utilizing specific HLA molecules to develop novel therapies to treat inflammatory diseases.”

New Survey of Federal Chief Data Officers Outlines Mission Challenges and Opportunities in the Age of AI

Retrieved on:

Tuesday, December 19, 2023

Federal, Evidence Act, CDO, Government, CIO, Federation, AI, Artificial intelligence, Management

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The Data Foundation, in collaboration with Deloitte*, unveiled the 2023 Federal Chief Data Officer (CDO) Survey, which found that federal CDOs made much progress advancing data culture, governance, and analytics goals, but still experience consistent challenges accessing adequate resources, staff skills, and authorities.

Key Points:

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The Data Foundation, in collaboration with Deloitte*, unveiled the 2023 Federal Chief Data Officer (CDO) Survey , which found that federal CDOs made much progress advancing data culture, governance, and analytics goals, but still experience consistent challenges accessing adequate resources, staff skills, and authorities.
The 2023 Federal CDO Survey also found that CDOs plan to embrace artificial intelligence (AI) platforms and other emerging technology in 2024.
In order to successfully leverage these cutting-edge technologies, federal CDOs say they need more clarification from agency leadership about their roles and responsibilities.
The report on the survey, Enabling Mission Success: A 2023 Survey of Federal Chief Data Officers, offers insight into the evolving role of the federal CDO since the implementation of the Foundations for Evidence-Based Policymaking Act, including the factors that enable and hinder CDO missions.